RxDoctor Payments Data

Amy Blue

Optometrist · Marion, VANPI 1639307010

Payments from drug & device makers

$2,320in general payments, 2019–2025

Across 91 payments — averaging $25.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$679
  • Coopervision Inc.$520
  • Mallinckrodt Hospital Products Inc.$362
  • Tarsus Pharmaceuticals, Inc.$148
  • Biotissue Holdings Inc.$111
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$92
  • plus $409 from 9 others

What the payments were for

  • Food & beverage$2,320100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,320 in reported general payments places this provider in the 75th percentile of 1,230 optometrist providers in Virginia.

See all optometrist providers in Virginia

Medicare billing

Part B allowed, 2024
$124,884
Medicare patients
453
Services billed
5,961

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine153$103,833
LumiganBimatoprost73$45,430
XiidraLifitegrast26$17,866
Cyclosporine40$14,411
CombiganBrimonidine Tartrate/Timolol23$5,545
Brimonidine Tartrate50$2,836
Ketorolac Tromethamine66$1,969
Prednisolone Acetate68$1,833
Latanoprost232$1,465
Travoprost16$1,035
Timolol Maleate76$659
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat35$605
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha48$570
Dorzolamide Hcl14$208
ErythromycinErythromycin Base17$191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$61$154,808249 claims
Bausch & Lomb Americas Inc.Xiidra$23$17,86626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,230 optometrist providers in Virginia.

Other optometrist in Marion

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →